8-K: EyePoint Advances DURAVYU Phase 3, Boosts Cash to $300M

EyePoint, Inc. provides a corporate update, highlighting progress in its DURAVYU Phase 3 trials for wet AMD and DME, and reports a strong cash position of approximately $300 million.

Summary

• EyePoint, Inc. issued a corporate update and anticipated 2026 pivotal milestones for its lead product candidate, DURAVYU (vorolanib intravitreal insert).
• Preliminary cash and investments were approximately $300 million as of December 31, 2025, providing a cash runway into the fourth quarter of 2027.
• This cash runway extends beyond key milestones for the Phase 3 wet AMD program in 2026 and fully funds the Phase 3 pivotal DME program.
• Enrollment for the Phase 3 LUGANO and LUCIA trials in wet AMD was completed with over 900 patients in 7 months, positioning DURAVYU as potentially first to market among investigational sustained delivery programs.
• Topline data for the LUGANO wet AMD trial is anticipated beginning in mid-2026, with LUCIA data to follow closely.
• First patient dosing in the Phase 3 DME trials (COMO and CAPRI) is expected in the first quarter of 2026, with each trial enrolling approximately 240 patients.
• Interim masked safety data through September 29, 2025, for the LUGANO and LUCIA trials remains consistent with previous DURAVYU clinical trials, and the independent Data Safety Monitoring Committee (DSMC) recommended continuation.
• DURAVYU registration batches are being manufactured at EyePoint's commercial facility to support the chemistry, manufacturing, and controls (CMC) section of a planned NDA filing.
• The company completed an underwritten public offering with gross proceeds of $172.5 million in October 2025.
• DURAVYU's multi-mechanism of action, including inhibition of IL-6 mediated inflammation and VEGF-mediated vascular permeability, was presented at Eyecelerator in October 2025.
• EyePoint will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.

Sentiment

Score: 8

Explanation: The filing presents a highly positive outlook, highlighting significant progress in clinical trials, strong financial health with an extended cash runway, and adherence to timelines for key milestones. The company emphasizes its potential to disrupt major markets with a differentiated product.

Positives

• Strong preliminary cash and investments of approximately $300 million as of December 31, 2025.
• Cash runway extends into Q4 2027, covering key Phase 3 wet AMD milestones and fully funding the Phase 3 DME program.
• Rapid enrollment of over 900 patients in Phase 3 wet AMD trials (LUGANO and LUCIA) in 7 months, positioning DURAVYU as potentially first to market among sustained delivery programs.
• Phase 3 wet AMD trials are on track for topline data readout beginning mid-2026.
• Phase 3 DME program first patient dosing expected in Q1 2026, remaining on schedule.
• Interim masked safety data for wet AMD trials is consistent with previous trials, and the DSMC recommended continuation without modifications.
• DURAVYU's unique multi-mechanism of action (IL-6 and VEGF inhibition) and sustained delivery profile offer a differentiated therapeutic approach.
• Successful underwritten public offering in October 2025, raising $172.5 million in gross proceeds.

Risks

• Uncertainties regarding the timing, progress, and results of clinical development activities, including DURAVYU.
• Uncertainties and delays relating to communications with the U.S. Food and Drug Administration (FDA) and the ability to obtain regulatory approval for DURAVYU.
• Unanticipated costs and expenses.
• The company's cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated.
• Risk that results of clinical trials may not be predictive of future results, and interim/preliminary data are subject to further analysis and may change.
• Unexpected safety or efficacy data observed during clinical trials.
• Uncertainties related to the regulatory authorization or approval process and available development and regulatory pathways.
• Changes in the regulatory environment, including disruptions at the FDA.
• Changes in U.S. and international trade policies.
• Changes in expected or existing competition.
• The success of current and future license agreements.
• Dependence on contract research organizations and other outside vendors.
• Product liability.
• Impact of general business and economic conditions.
• Protection of intellectual property and avoiding infringement.
• Retention of key personnel.
• Delays, interruptions, or failures in the manufacture and supply of product candidates.
• Availability of and need for additional financing.
• Ability to obtain additional funding to support clinical development programs.
• Uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts.
• Uncertainties regarding the FDA warning letter pertaining to the company's Watertown, MA manufacturing facility.

Future Outlook

EyePoint anticipates a milestone-rich 2026, with topline data from its Phase 3 wet AMD program expected to begin in mid-2026, followed by an expeditious NDA filing and FDA review. The company also expects to dose the first patient in its Phase 3 DME program in Q1 2026, aiming to solidify DURAVYU's position as a sustained release TKI for this multi-billion-dollar indication. The cash runway is projected to extend into Q4 2027, funding operations beyond these key milestones.

Management Comments

• "Following an incredibly successful year of execution in 2025, EyePoint is positioned to deliver on key priorities across both of our late-stage programs, wet AMD and DME, in 2026." Jay S. Duker, M.D., President and Chief Executive Officer.
• "As we prepare for a milestone-rich year, we continue to be guided by scientific rigor, a de-risked clinical approach, and a patient-centric focus that define our principles." Jay S. Duker, M.D., President and Chief Executive Officer.
• "With topline data from our Phase 3 wet AMD program anticipated beginning in mid-2026, we are actively preparing for an expeditious NDA filing and FDA review to ensure we deliver DURAVYU to patients as soon as possible." Jay S. Duker, M.D., President and Chief Executive Officer.
• "Additionally, we remain on track to dose the first patient in our Phase 3 DME program in the first quarter of 2026, further solidifying DURAVYU’s position as the only sustained release TKI in development for this multi-billion-dollar indication for which there is a significant need for new therapeutic options." Jay S. Duker, M.D., President and Chief Executive Officer.
• "DURAVYU is uniquely poised to potentially disrupt the largest retinal disease markets, with a unique multi-mechanism of action, and a compelling profile within the retinal disease community." Jay S. Duker, M.D., President and Chief Executive Officer.

Industry Context

The announcement positions DURAVYU as a potential disruptor in the multi-billion-dollar retinal disease markets (wet AMD and DME), which currently have significant unmet needs for new therapeutic options, particularly sustained-delivery treatments. Its multi-mechanism of action (VEGF and IL-6 inhibition) and sustained release profile aim to offer a differentiated approach compared to existing anti-VEGF therapies, potentially reducing treatment burden for patients and addressing a significant market opportunity.

Comparison to Industry Standards

• DURAVYU's Phase 3 wet AMD program completed enrollment of over 900 patients in 7 months, described as "one of the fastest enrolling wet AMD pivotal programs," potentially positioning it as "first to market among all current investigational sustained delivery programs."
• The LUGANO and LUCIA trials utilize an on-label aflibercept control, a current standard of care, for noninferiority comparison, aligning with established regulatory pathways.
• The Phase 2 VERONA trial in DME demonstrated meaningful early and sustained improvements in vision and anatomy compared to aflibercept 2mg, suggesting competitive efficacy.
• The DAVIO 2 Phase 2 trial in wet AMD showed an 88% reduction in treatment burden six months after treatment, with over 80% of patients supplement-free or receiving only one supplemental anti-VEGF injection, indicating a potentially superior dosing interval compared to current anti-VEGF injection regimens.

Legal Proceedings

• Uncertainties regarding the timing and results of the August 2022 subpoena from the U.S. Attorney's Office for the District of Massachusetts.
• Uncertainties regarding the FDA warning letter pertaining to the company's Watertown, MA manufacturing facility.

Stakeholder Impact

• Shareholders: Positive impact due to strong cash position, extended runway, on-track clinical development, and potential for market disruption and first-to-market advantage.
• Patients: Potential for a new, sustained-delivery treatment option (DURAVYU) that could reduce treatment burden and improve lives for those with wet AMD and DME.
• Employees: Continued stability and progress in development programs.
• Regulatory Authorities: Ongoing engagement with FDA and EMA for trial alignment and future NDA filing.

Next Steps

• Topline data readout for Phase 3 LUGANO wet AMD trial beginning in mid-2026.
• Topline data for Phase 3 LUCIA wet AMD trial to closely follow LUGANO.
• Expeditious NDA filing and FDA review for DURAVYU in wet AMD, if Phase 3 data is positive.
• First patient dosing in Phase 3 DME trials (COMO and CAPRI) in Q1 2026.
• Presenting at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
• Presenting a clinical trial update for DURAVYU for retinal exudative diseases at the Hawaiian Eye and Retina 2026 conference.

Key Dates

Recommendation

The filing indicates significant positive momentum for EyePoint. The strong cash position of $300 million provides a runway into Q4 2027, fully funding critical Phase 3 programs for both wet AMD and DME. The rapid enrollment in wet AMD trials and being on track for mid-2026 topline data, coupled with the imminent start of DME trials, de-risks the clinical development pathway. DURAVYU's potential as a first-to-market sustained delivery therapy with a unique multi-mechanism of action in multi-billion-dollar markets suggests substantial future revenue potential. The positive interim safety data and DSMC recommendation further bolster confidence. While regulatory risks and a past subpoena/FDA warning letter are noted, the overall progress and financial health present a compelling investment case for long-term growth.

Keywords

Retinal diseases, wet AMD, DME, DURAVYU, vorolanib, sustained delivery, Phase 3 trials, clinical development, biopharmaceutical, TKI, Durasert E, FDA, NDA, cash runway, J.P. Morgan Healthcare Conference